177 related articles for article (PubMed ID: 37417561)
21. The Prostate Health Index aids multi-parametric MRI in diagnosing significant prostate cancer.
Fan YH; Pan PH; Cheng WM; Wang HK; Shen SH; Liu HT; Cheng HM; Chen WR; Huang TH; Wei TC; Huang IS; Lin CC; Huang EYH; Chung HJ; Huang WJS; Lin TP
Sci Rep; 2021 Mar; 11(1):1286. PubMed ID: 33674631
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Prostate-Specific Antigen and Its Density and Prostate Health Index and Its Density for Detection of Prostate Cancer.
Boo Y; Chung JH; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Song W
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509551
[TBL] [Abstract][Full Text] [Related]
23. Risk factor analysis and optimal cutoff value selection of PSAD for diagnosing clinically significant prostate cancer in patients with negative mpMRI: results from a high-volume center in Southeast China.
Lin S; Jiang W; Ding J; Hao S; Chen H; Xie L; Zheng X
World J Surg Oncol; 2024 May; 22(1):140. PubMed ID: 38802859
[TBL] [Abstract][Full Text] [Related]
24. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
[TBL] [Abstract][Full Text] [Related]
25. Prostate-specific Antigen Parameters and Prostate Health Index Enhance Prostate Cancer Prediction With the In-bore 3-T Magnetic Resonance Imaging-guided Transrectal Targeted Prostate Biopsy After Negative 12-Core Biopsy.
Friedl A; Stangl K; Bauer W; Kivaranovic D; Schneeweiss J; Susani M; Hruby S; Lusuardi L; Lomoschitz F; Eisenhuber-Stadler E; Schima W; Brössner C
Urology; 2017 Dec; 110():148-153. PubMed ID: 28844600
[TBL] [Abstract][Full Text] [Related]
26. The role of prostate-specific antigen density and negative multiparametric magnetic resonance imaging in excluding prostate cancer for biopsy-naïve men: clinical outcomes from a high-volume center in China.
Zhang CC; Tu X; Lin TH; Cai DM; Yang L; Nie L; Qiu S; Liu ZH; Jin K; Li JK; Xiong XY; Yang L; Wei Q
Asian J Androl; 2022; 24(6):615-619. PubMed ID: 35532555
[TBL] [Abstract][Full Text] [Related]
27. Combining prostate health index and multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer in an Asian population.
Hsieh PF; Li WJ; Lin WC; Chang H; Chang CH; Huang CP; Yang CR; Chen WC; Chang YH; Wu HC
World J Urol; 2020 May; 38(5):1207-1214. PubMed ID: 31440806
[TBL] [Abstract][Full Text] [Related]
28. Modified Prostate Health Index Density Significantly Improves Clinically Significant Prostate Cancer (csPCa) Detection.
Chen H; Qian Y; Wu Y; Shi B; Zhou J; Qu F; Gu Z; Ding J; Yu Y
Front Oncol; 2022; 12():864111. PubMed ID: 35463344
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study.
Kim JY; Yu JH; Sung LH; Cho DY; Kim HJ; Yoo SJ
BMC Urol; 2021 Sep; 21(1):131. PubMed ID: 34530786
[TBL] [Abstract][Full Text] [Related]
30. Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance.
Schwen ZR; Mamawala M; Tosoian JJ; Druskin SC; Ross AE; Sokoll LJ; Epstein JI; Carter HB; Gorin MA; Pavlovich CP
BJU Int; 2020 Sep; 126(3):373-378. PubMed ID: 32367635
[TBL] [Abstract][Full Text] [Related]
31. Utility of Prostate Health Index Density for Biopsy Strategy in Biopsy-Naïve Patients With PI-RADS v2.1 Category 3 Lesions.
Kim MJ; Park JJ; Kang KA; Park SY; Kim CK
J Magn Reson Imaging; 2024 Feb; ():. PubMed ID: 38299766
[TBL] [Abstract][Full Text] [Related]
32. The prostate health index (PHI) density: Are there advantages over PHI or over the prostate-specific antigen density?
Garrido MM; Ribeiro RM; Pinheiro LC; Holdenrieder S; Guimarães JT
Clin Chim Acta; 2021 Sep; 520():133-138. PubMed ID: 34097882
[TBL] [Abstract][Full Text] [Related]
33. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
[TBL] [Abstract][Full Text] [Related]
34. Cutoff Values of Prostate Imaging Reporting and Data System Version 2.1 Score in Men With Prostate-specific Antigen Level 4 to 10 ng/mL: Importance of Lesion Location.
Chen Y; Ruan M; Zhou B; Hu X; Wang H; Liu H; Liu J; Song G
Clin Genitourin Cancer; 2021 Aug; 19(4):288-295. PubMed ID: 33632569
[TBL] [Abstract][Full Text] [Related]
35. The use of
Yang J; Tang Y; Zhou C; Zhou M; Li J; Hu S
Prostate; 2023 Apr; 83(5):430-439. PubMed ID: 36544382
[TBL] [Abstract][Full Text] [Related]
36. Do PHI and PHI density improve detection of clinically significant prostate cancer only in the PSA gray zone?
Rius Bilbao L; Valladares Gomez C; Aguirre Larracoechea U; Pereira Arias JG; Arredondo Calvo P; Urdaneta Salegui LF; Escobal Tamayo V; Sanz Jaka JP; Recio Ayesa A; Mar Medina J; Mar Medina C
Clin Chim Acta; 2023 Mar; 542():117270. PubMed ID: 36893880
[TBL] [Abstract][Full Text] [Related]
37. Use of the Prostate Health Index and Density in 3 Outpatient Centers to Avoid Unnecessary Prostate Biopsies.
Schulze A; Christoph F; Sachs M; Schroeder J; Stephan C; Schostak M; Koenig F
Urol Int; 2020; 104(3-4):181-186. PubMed ID: 32224611
[TBL] [Abstract][Full Text] [Related]
38. The function of Prostate Health Index in detecting clinically significant prostate cancer in the PI-RADS 3 population: a multicenter prospective study.
Zhou Y; Fu Q; Shao Z; Qi W; Zhong M; Lv G; Jiang Z; Zhu M; Wang W; Shi B; Chen S; Zhu Y
World J Urol; 2023 Feb; 41(2):455-461. PubMed ID: 36592177
[TBL] [Abstract][Full Text] [Related]
39. [The clinical decision-making value of prostate specific antigen and its derived indicators in prostate imaging reporting and data system version 2 3 lesions].
Yang S; Zhang YY; Zhao WL; Wei CG; Chen T; Li MJ; Tan SX; Shen JK
Zhonghua Yi Xue Za Zhi; 2020 Apr; 100(13):997-1001. PubMed ID: 32294856
[No Abstract] [Full Text] [Related]
40. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
